Add Company
Join Now

KaliVir Immunotherapeutics Revenue and Competitors

License our Company Data API

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • KaliVir Immunotherapeutics's estimated annual revenue is currently $4.5M per year.(i)
  • KaliVir Immunotherapeutics's estimated revenue per employee is $100,500

Employee Data

  • KaliVir Immunotherapeutics has 45 Employees.(i)
  • KaliVir Immunotherapeutics grew their employee count by 55% last year.

KaliVir Immunotherapeutics's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
Chief Financial OfficerReveal Email/Phone
3
ControllerReveal Email/Phone
4
SVP Clinical OperationsReveal Email/Phone
5
Chief Scientific OfficerReveal Email/Phone
6
Associate Director, Process DevelopmentReveal Email/Phone
7
Director Operations, GMP ManufacturingReveal Email/Phone
8
Director Technical OperationsReveal Email/Phone
9
Director ImmunologyReveal Email/Phone
10
Chief Medical OfficerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$46.6M2328%N/AN/A
#2
$84.2M4193%N/AN/A
#3
$14.1M700%N/AN/A
#4
$1224.3M6091-9%N/AN/A
#5
$43.2M215-4%N/AN/A
#6
$12.3M61-6%N/AN/A
#7
$19.9M9941%N/AN/A
#8
$16.5M82-5%N/AN/A
#9
$97.7M48630%N/AN/A
#10
$12.5M62-16%N/AN/A
Add Company

What Is KaliVir Immunotherapeutics?

KaliVir Immunotherapeutics was founded in 2019 to pioneer a unique and novel approach to cancer treatment that engages a virus’ natural ability to replicate in and kill cancer cells. This modality is known as oncolytic viral immunotherapy. KaliVir’s cutting-edge, next generation oncolytic viral immunotherapy programs combine technologies developed in-house and licensed from University of Pittsburgh’s world-class oncolytic virus and immunotherapy research programs.

keywords:N/A

N/A

Total Funding

45

Number of Employees

$4.5M

Revenue (est)

55%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$9.7M4515%N/A
#2
$11.6M455%N/A
#3
$7.6M457%N/A
#4
$9M45-4%N/A
#5
$9.7M4510%N/A